>Mercado europeu de dor ocular, por tipo de doença (dor ocular com doenças oculares e dor ocular sem doenças oculares primárias), tipo (diagnóstico e tratamento), aplicação (conjuntivite, abrasão da córnea, blefarite, pocilga, irite, sinusite, enxaqueca, glaucoma e Outros), Via de Administração (Tópica, Periocular, Intra-Ocular, Oral e Outros), Tipo de Medicamento (Prescrito e de Venda Livre), Tipo de População (Adultos e Geriátricos), Utilizador Final (Hospitais, Clínicas Especializadas, Centros de Saúde Domiciliária, Centros Oftalmológicos , Centros Cirúrgicos Ambulatório e Outros), Canal de Distribuição (Concurso Directo, Farmácia Hospitalar, Farmácia de Retalho, Farmácia Online e Outros), País (Reino Unido, Alemanha, França, Espanha, Itália, Holanda, Suíça, Rússia, Hungria, Lituânia, Áustria, Irlanda, Noruega, Polónia, Turquia e Resto da Europa) – Tendências e previsões da indústria para 2028.
Análise de Mercado e Insights: Mercado Europeu de Dor Ocular
O mercado europeu de dor ocular deverá crescer no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 7,0% no período de previsão de 2021 a 2028 e deverá atingir 335,30 milhões de dólares até 2028. O aumento do estilo de vida pouco higiénico e sedentário atua como um motor para o crescimento do mercado europeu de dor ocular.
A dor também ocular, conhecida como dor ocular, ocorre geralmente devido a uma irritação ligeira , mas raramente é um sintoma de uma doença grave. Principalmente a dor desaparece sem medicação ou tratamento adicional e recupera através do sistema autoimune. No entanto, a dor ocular com distúrbios oftálmicos primários subjacentes requer um tratamento atempado. As dores oculares são geralmente categorizadas em duas categorias, como a dor ocular, que ocorre na superfície do olho, criando sensações de comichão, ardor ou prurido. São causados por cílios, objetos estranhos, infeção ou trauma de uma pessoa. Frequentemente, a dor ocular é tratada com colírios e esteróides tópicos ou AINE. A dor ocular ocorre com doenças oculares primárias subjacentes, como conjuntivite, irritação das lentes de contacto , abrasão da córnea, lesão, blefarite e pocilga. Os outros tratamentos avançados, como as terapias de estimulação, são também utilizados para as dores neurooculares graves, devidamente diagnosticadas.
O aumento do estilo de vida pouco higiénico e sedentário, o aumento da prevalência de distúrbios oftalmológicos e a dor ocular atuam como impulsionadores do mercado europeu da dor ocular. A crescente consciencialização das pessoas sobre as doenças oculares e os casos crescentes de enxaqueca ocular está a impulsionar ainda mais o crescimento do mercado. Os efeitos secundários dos medicamentos para o tratamento oftalmológico e o elevado custo do tratamento e medicação oftalmológica estão a restringir o crescimento do mercado europeu da dor ocular. O aumento das atividades de investigação e desenvolvimento, o aumento das despesas com os cuidados de saúde e do rendimento disponível e o crescimento da população geriátrica funcionam como oportunidades para o mercado europeu da dor ocular. A falta de instalações de saúde para tratamento oftalmológico e um quadro regulamentar rigoroso funcionam como desafios para o crescimento do mercado europeu da dor ocular.
O relatório do mercado europeu de dor ocular fornece detalhes da quota de mercado, novos desenvolvimentos e análise do pipeline de produtos, o impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações do mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado da dor ocular, contacte a Data Bridge Market Research para obter um resumo do analista; a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir a meta desejada.
Âmbito do mercado europeu de dor ocular e dimensão do mercado
O mercado europeu da dor ocular está segmentado com base no tipo de doença, tipo, aplicação, via de administração, tipo de medicamento, tipo de população, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no tipo de doença, o mercado europeu da dor ocular está segmentado em dor ocular com doenças oculares e dor ocular sem doenças oculares primárias. Em 2021, prevê-se que o segmento da dor ocular com doenças oculares domine o mercado da dor ocular devido ao elevado número de casos de distúrbios oftálmicos cirúrgicos.
- Com base no tipo, o mercado europeu da dor ocular está segmentado em diagnóstico e tratamento. Em 2021, espera-se que o segmento de diagnóstico domine o mercado, uma vez que o diagnóstico é altamente especificado para opções de tratamento oportunas.
- Com base na aplicação, o mercado europeu da dor ocular está segmentado em conjuntivite, abrasão da córnea, blefarite, pocilga, irite, sinusite, enxaquecas, glaucoma, entre outros. Em 2021, prevê-se que o segmento do glaucoma domine o mercado, uma vez que este é o principal distúrbio oftalmológico da região.
- Com base na via de administração, o mercado europeu da dor ocular está segmentado em tópico, periocular, intraocular, oral, entre outros. Em 2021, espera-se que o segmento tópico domine o mercado, uma vez que fornece tratamento em fase inicial para os principais distúrbios oftalmológicos e condições de dor ocular.
- Com base no tipo de medicamento, o mercado europeu da dor ocular está segmentado em prescrição e venda livre. Em 2021, prevê-se que o segmento da prescrição domine o mercado, uma vez que a comunidade prefere principalmente o tratamento hospitalar com uma prescrição adequada de medicamentos mais seguros.
- Com base no tipo populacional, o mercado europeu da dor ocular está segmentado em adultos e geriátricos. Em 2021, prevê-se que o segmento dos adultos domine o mercado devido ao aumento da população adulta e dos alunos internos localizados na região.
- Com base no utilizador final, o mercado europeu da dor ocular está segmentado em hospitais, clínicas especializadas, cuidados domiciliários, centros oftalmológicos, centros de cirurgia ambulatória, entre outros. Em 2021, prevê-se que o segmento hospitalar domine o mercado devido aos elevados avanços tecnológicos.
- Com base no canal de distribuição, o mercado europeu da dor ocular está segmentado em concurso direto, farmácia hospitalar, farmácia de retalho, farmácia online, entre outros. Em 2021, prevê-se que o segmento do concurso direto domine o mercado, uma vez que as empresas envolvem diretamente a distribuição e não os retalhistas.
Análise a nível de país do mercado europeu de dor ocular
O mercado europeu da dor ocular é analisado e são fornecidas informações sobre o tamanho do mercado por país, tipo de doença, tipo, aplicações, via de administração, tipo de medicamento, tipo de população, utilizador final e canal de distribuição como mencionado acima .
Os países abrangidos pelo relatório do mercado europeu da dor ocular são o Reino Unido, Alemanha, França, Espanha, Itália, Países Baixos, Suíça, Rússia, Turquia, Áustria, Irlanda e o resto da Europa.
Prevê-se que o segmento de diagnóstico na região Alemanha da Europa cresça com a maior taxa de crescimento no período de previsão de 2021 a 2028 devido aos crescentes avanços tecnológicos. O segmento de diagnóstico em Itália é o segundo mercado dominante na região europeia devido ao estilo de vida cada vez mais sedentário das pessoas. A França é o terceiro mercado líder, e espera-se que o segmento de diagnóstico domine aqui devido à crescente consciencialização sobre os principais distúrbios da dor ocular.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e disponibilidade de marcas europeias e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto dos canais de vendas são considerados ao mesmo tempo que fornecem uma análise de previsão dos dados do país.
O crescimento das atividades estratégicas dos principais players do mercado para aumentar a consciencialização sobre o tratamento da dor ocular está a impulsionar o crescimento do mercado europeu da dor ocular
O mercado da dor ocular também fornece uma análise de mercado detalhada para o crescimento de cada país num mercado específico. Além disso, fornece informação detalhada sobre a estratégia dos intervenientes no mercado e a sua presença geográfica. Os dados estão disponíveis para o período histórico de 2010 a 2019.
Cenário competitivo e análise da quota de mercado da dor ocular na Europa
O cenário competitivo do mercado europeu de dor ocular fornece detalhes do concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura do produto, e amplitude, domínio de aplicação, curva de segurança tecnológica. Os dados acima fornecidos estão apenas relacionados com o foco da empresa no mercado europeu da dor ocular.
As principais empresas que negoceiam no mercado europeu da dor ocular são a Johnson & Johnson Services, Inc., a Pfizer Inc., a EyePoint Pharmaceuticals, Inc., a Merck Sharp & Dohme Corp., uma subsidiária da Merck & Co., Inc., a Akorn Operating Company LLC, AERIE PHARMACEUTICALS, INC., Sun Pharmaceutical Industries Ltd., Bausch & Lomb Incorporated, Ocular Therapeutix, Inc., Novartis AG, Allergan (uma empresa AbbVie), Sylentis, Pharmaleads SA, OKYO Pharma Limited., Novaliq GmbH e entre outros são jogadores nacionais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos contratos e acordos são também iniciados por empresas de todo o mundo, o que acelera o mercado europeu da dor ocular.
Por exemplo,
- Em março de 2021, o produto para a doença do olho seco SYL1001_V da Sylentis com solução oftálmica de tivanisiran (colírio) no seu portefólio de produtos oftalmológicos atingiu com sucesso o ensaio clínico de fase III. Este progresso é previsto no lançamento do produto logo após um teste bem sucedido, melhorando assim o seu perfil global.
- Em setembro de 2019, a Pharmaleads SA participou na Conferência Internacional sobre Cefaleias realizada em Dublin. A empresa colaborou com Radhouane Dallel, da Université de Clermont-Ferrand, situada em França, e apresentou um poster com os resultados clínicos do produto PL37 utilizado para enxaquecas agudas e crónicas. Isto aumentou o reconhecimento global da empresa
A colaboração, o lançamento de produtos, a expansão do negócio, a atribuição de prémios e reconhecimento, as joint ventures e outras estratégias do player de mercado potenciam a presença da empresa no mercado da dor ocular, o que beneficia também o crescimento do lucro da organização.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE OCULAR PAIN MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 EUROPE OCULAR PAIN MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISEASE TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
4.3 AVERAGE PRICING ANALYSIS OF VARIOUS TREATMENT OPTIONS
4.4 VOLUME OF PRESCRIPTION
5 PIPELINE ANALYSIS
6 REGIONAL SUMMARY
6.1 NORTH AMERICA
6.2 EUROPE
6.3 ASIA-PACIFIC
6.4 SOUTH AMERICA
6.5 THE MIDDLE EAST AND AFRICA
7 EUROPE OCULAR PAIN MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE
8.1.2 RISING PREVALENCE OF OPHTHALMIC DISORDERS AND OCULAR PAINS
8.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES
8.1.4 GROWING CASES OF OCULAR MIGRAINE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF EYE TREATMENT MEDICINES
8.2.2 HIGH COST OF EYE TREATMENT AND MEDICATION
8.3 OPPORTUNITIES
8.3.1 RISING HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
8.3.3 INCREASING GERIATRIC POPULATION
8.4 CHALLENGES
8.4.1 STRINGENT RULES & REGULATIONS
8.4.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT
9 IMPACT OF COVID-19 PANDEMIC ON THE EUROPE OCULAR PAIN MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 EUROPE OCULAR PAIN MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 OCULAR PAIN WITH EYE DISEASES
10.2.1 OCULAR PAIN WITH RED EYE
10.2.2 OCULAR PAIN WITHOUT RED EYE
10.3 OCULAR PAIN WITHOUT PRIMARY EYE DISEASES
10.3.1 OCULAR MIGRAINE
10.3.2 GIANT CELL ARTERITIS
10.3.3 TRIGEMINAL NEURALGIAS
10.3.4 CAVERNOUS SINUS AND SUPERIOR FISSURE PROCESSES
10.3.5 CAROTID ARTERY DISSECTION
10.3.6 CAROTIDYNIA
10.3.7 OTHERS
11 EUROPE OCULAR PAIN MARKET, BY TYPE
11.1 OVERVIEW
11.2 DIAGNOSIS
11.2.1 SENSORY TESTING
11.2.1.1 HAND LIGHT EXAMINATION
11.2.1.2 DIRECT OPHTHALMOSCOPIC EXAMINATIONS
11.2.1.3 SLIT LAMP EXAMINATION
11.2.1.4 FLUORESCEIN EXAMINATION
11.2.2 IMAGING TEST
11.2.2.1 CONFOCAL MICROSCOPY
11.2.2.2 FUNCTIONAL MRI
11.3 TREATMENT
11.3.1 LOCAL TREATMENT
11.3.1.1 TOPICAL STEROID
11.3.1.1.1 LOTEPREDNOL
11.3.1.1.2 DEXAMETHASONE
11.3.1.1.3 PREDNISOLONE
11.3.1.1.4 FLUOROMETHOLONE
11.3.1.1.5 OTHERS
11.3.1.2 NONSTEROIDAL ANTI-INFLAMMATORY (NSAID)
11.3.1.2.1 BROMFENAC
11.3.1.2.2 KETOROLAC
11.3.1.2.3 NEPAFENAC
11.3.1.2.4 DICLOFENAC
11.3.1.2.5 OTHERS
11.3.1.3 OTHERS
11.3.2 STIMULATION THERAPIES
11.3.2.1 DEEP BRAIN STIMULATION
11.3.2.2 TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)
11.3.2.3 REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS)
11.3.2.4 SCRAMBLER THERAPY
11.3.2.5 OTHERS
11.3.3 OTHERS
12 EUROPE OCULAR PAIN MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 GLAUCOMA
12.3 BLEPHARITIS
12.4 CONJUNCTIVITIS
12.5 CORNEAL ABRASION
12.6 STY
12.7 IRITIS
12.8 SINUSITIS
12.9 MIGRAINES
12.1 OTHERS
13 EUROPE OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 TOPICAL
13.2.1 SOLUTION
13.2.2 GELS
13.2.3 OINTMENTS
13.2.4 OTHERS
13.3 INTRAOCULAR
13.3.1 INTRAVITREAL
13.3.2 INTRACAMERAL
13.4 PERIOCULAR
13.4.1 SUBCONJUNCTIVAL
13.4.2 SUBTENON
13.4.3 PERIBULBAR
13.4.4 RETROBULBAR
13.5 ORAL
13.5.1 TABLETS
13.5.2 CAPSULE
13.5.3 OTHERS
13.6 OTHERS
14 EUROPE OCULAR PAIN MARKET, BY DRUG TYPE
14.1 OVERVIEW
14.2 PRESCRIPTION
14.3 OVER THE COUNTER
15 EUROPE OCULAR PAIN MARKET, BY POPULATION TYPE
15.1 OVERVIEW
15.2 ADULTS
15.3 GERIATRIC
16 EUROPE OCULAR PAIN MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CLINICS
16.4 HOME HEALTHCARE
16.5 OPHTHALMOLOGY CENTERS
16.6 AMBULATORY SURGICAL CENTERS
16.7 OTHERS
17 EUROPE OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 HOSPITAL PHARMACY
17.4 RETAIL PHARMACY
17.5 ONLINE PHARMACY
17.6 OTHERS
18 EUROPE OCULAR PAIN MARKET, BY GEOGRAPHY
18.1 EUROPE
18.1.1 GERMANY
18.1.2 ITALY
18.1.3 FRANCE
18.1.4 U.K.
18.1.5 SPAIN
18.1.6 NETHERLANDS
18.1.7 RUSSIA
18.1.8 SWITZERLAND
18.1.9 TURKEY
18.1.10 AUSTRIA
18.1.11 NORWAY
18.1.12 HUNGARY
18.1.13 LITHUANIA
18.1.14 IRELAND
18.1.15 POLAND
18.1.16 REST OF EUROPE
19 EUROPE OCULAR PAIN MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: EUROPE
20 SWOT ANALYSIS
21 COMPANY PROFILE
21.1 BAUSCH & LOMB INCORPORATED
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 NOVARTIS AG
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENT
21.4 OMEROS CORPORATION
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENTS
21.5 AKORN OPERATING COMPANY LLC
21.5.1 COMPANY SNAPSHOT
21.5.2 COMPANY SHARE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENTS
21.6 AERIE PHARMACEUTICALS, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ALDEYRA THERAPEUTICS, INC.
21.7.1 COMPANY SNAPSHOT
21.7.2 PRODUCT PORTFOLIO
21.7.3 RECENT DEVELOPMENTS
21.8 ALLAKOS INC.
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENT
21.9 ALLERGAN (AN ABBVIE COMPANY)
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENTS
21.1 EYEPOINT PHARMACEUTICALS, INC.
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENTS
21.11 FERA PHARMACEUTICALS
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENTS
21.12 FORMOSAPHARMA PHARMACEUTICAL INC.
21.12.1 COMPANY SNAPSHOT
21.12.2 PRODUCT PORTFOLIO
21.12.3 RECENT DEVELOPMENT
21.13 IACTA PHARMACEUTICALS, INC.
21.13.1 COMPANY SNAPSHOT
21.13.2 PRODUCT PORTFOLIO
21.13.3 RECENT DEVELOPMENTS
21.14 JOHNSON & JOHNSON SERVICES, INC.
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 KALA PHARMACEUTICALS
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 NOVALIQ GMBH
21.17.1 COMPANY SNAPSHOT
21.17.2 PRODUCT PORTFOLIO
21.17.3 RECENT DEVELOPMENTS
21.18 OCULAR THERAPEUTIX, INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 OKYO PHARMA LIMITED
21.19.1 COMPANY SNAPSHOT
21.19.2 PRODUCT PORTFOLIO
21.19.3 RECENT DEVELOPMENTS
21.2 PFIZER, INC.
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 PHARMALEADS SA
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENT
21.22 SITEONE THERAPEUTICS, INC.
21.22.1 COMPANY SNAPSHOT
21.22.2 PRODUCT PORTFOLIO
21.22.3 RECENT DEVELOPMENT
21.23 SYLENTIS
21.23.1 COMPANY SNAPSHOT
21.23.2 PRODUCT PORTFOLIO
21.23.3 RECENT DEVELOPMENT
21.24 TALLC INC.
21.24.1 COMPANY SNAPSHOT
21.24.2 PRODUCT PORTFOLIO
21.24.3 RECENT DEVELOPMENT
21.25 TARSIER PHARMA LTD.
21.25.1 COMPANY SNAPSHOT
21.25.2 PRODUCT PORTFOLIO
21.25.3 RECENT DEVELOPMENT
21.26 VYLUMA
21.26.1 COMPANY SNAPSHOT
21.26.2 PRODUCT PORTFOLIO
21.26.3 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
Lista de Tabela
TABLE 1 AVERAGE PRICING ANALYSIS OF VARIOUS TREATMENT PRODUCTS
TABLE 2 VOLUME OF PRESCRIPTION (%)
TABLE 3 EUROPE OCULAR PAIN MARKET, PIPELINE ANALYSIS
TABLE 4 EUROPE OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 5 EUROPE OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 EUROPE OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 7 EUROPE OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 EUROPE OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 9 EUROPE OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 EUROPE DIAGNOSIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 EUROPE DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 EUROPE SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 13 EUROPE IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 EUROPE TREATMENT IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 EUROPE TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 EUROPE LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 EUROPE TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 EUROPE STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 EUROPE OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 21 EUROPE GLAUCOMA IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 EUROPE BLEPHARITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 EUROPE CONJUNCTIVITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 EUROPE CORNEAL ABRASION IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE STY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 EUROPE IRITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 EUROPE SINUSITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 EUROPE MIGRAINES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 EUROPE OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 EUROPE OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE TOPICAL IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 EUROPE TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE INTRAOCULAR IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 EUROPE INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 EUROPE PERIOCULAR IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 EUROPE PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 37 EUROPE ORAL IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 EUROPE ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 39 EUROPE OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 EUROPE OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 41 EUROPE PRESCRIPTION IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 EUROPE OVER THE COUNTER IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 EUROPE OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 44 EUROPE ADULTS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 EUROPE GERIATRIC IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 EUROPE OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 47 EUROPE HOSPITALS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 EUROPE SPECIALTY CLINICS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 EUROPE HOME HEALTHCARE IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 EUROPE OPHTHALMOLOGY CENTERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 EUROPE AMBULATORY SURGICAL CENTERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 EUROPE OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 EUROPE OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 54 EUROPE DIRECT TENDER IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 55 EUROPE HOSPITAL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 56 EUROPE RETAIL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 57 EUROPE ONLINE PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 58 EUROPE OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 59 EUROPE OCULAR PAIN MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 60 EUROPE OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 61 EUROPE OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 62 EUROPE OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 63 EUROPE OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 EUROPE DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 EUROPE SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 EUROPE IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 EUROPE TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 EUROPE LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 EUROPE TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 71 EUROPE STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 EUROPE OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 EUROPE OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 74 EUROPE TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 75 EUROPE INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 76 EUROPE PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 77 EUROPE ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 78 EUROPE OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 79 EUROPE OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 80 EUROPE OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 EUROPE OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 82 GERMANY OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 83 GERMANY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 84 GERMANY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 85 GERMANY OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 GERMANY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 GERMANY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 GERMANY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 GERMANY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 GERMANY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 GERMANY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 GERMANY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 GERMANY OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 95 GERMANY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 GERMANY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 GERMANY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 98 GERMANY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 99 GERMANY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 100 GERMANY OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 101 GERMANY OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 102 GERMANY OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 103 GERMANY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 104 ITALY OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 105 ITALY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 106 ITALY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 107 ITALY OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 ITALY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 ITALY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 ITALY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 ITALY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 ITALY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 ITALY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 ITALY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 ITALY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 ITALY OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 117 ITALY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 118 ITALY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 119 ITALY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 ITALY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 121 ITALY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 122 ITALY OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 123 ITALY OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 124 ITALY OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 ITALY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 126 FRANCE OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 127 FRANCE OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 128 FRANCE OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 129 FRANCE OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 FRANCE DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 FRANCE SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 FRANCE IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 FRANCE TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 FRANCE LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 FRANCE TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 136 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 FRANCE STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 FRANCE OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 139 FRANCE OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 140 FRANCE TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 141 FRANCE INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 142 FRANCE PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 143 FRANCE ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 144 FRANCE OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 145 FRANCE OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 146 FRANCE OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 147 FRANCE OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 148 U.K. OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 149 U.K. OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 150 U.K. OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 151 U.K. OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 152 U.K. DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 153 U.K. SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 U.K. IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 U.K. TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 U.K. LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 U.K. TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 U.K. NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 159 U.K. STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 160 U.K. OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 161 U.K. OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 162 U.K. TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 163 U.K. INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 164 U.K. PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 165 U.K. ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 166 U.K. OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 167 U.K. OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 168 U.K. OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 169 U.K. OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 170 SPAIN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 171 SPAIN OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 172 SPAIN OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 173 SPAIN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 SPAIN DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 SPAIN SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 SPAIN IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 SPAIN TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 SPAIN LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 179 SPAIN TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 180 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 181 SPAIN STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 182 SPAIN OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 183 SPAIN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 184 SPAIN TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 185 SPAIN INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 186 SPAIN PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 187 SPAIN ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 188 SPAIN OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 189 SPAIN OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 190 SPAIN OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 191 SPAIN OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 192 NETHERLANDS OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 193 NETHERLANDS OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 194 NETHERLANDS OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 195 NETHERLANDS OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 NETHERLANDS DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 197 NETHERLANDS SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 198 NETHERLANDS IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 199 NETHERLANDS TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 200 NETHERLANDS LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 201 NETHERLANDS TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 202 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 203 NETHERLANDS STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 204 NETHERLANDS OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 205 NETHERLANDS OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 206 NETHERLANDS TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 207 NETHERLANDS INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 208 NETHERLANDS PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 209 NETHERLANDS ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 210 NETHERLANDS OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 211 NETHERLANDS OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 212 NETHERLANDS OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 213 NETHERLANDS OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 214 RUSSIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 215 RUSSIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 216 RUSSIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 217 RUSSIA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 218 RUSSIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 219 RUSSIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 220 RUSSIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 221 RUSSIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 222 RUSSIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 223 RUSSIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 224 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 225 RUSSIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 226 RUSSIA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 227 RUSSIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 228 RUSSIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 229 RUSSIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 230 RUSSIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 231 RUSSIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 232 RUSSIA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 233 RUSSIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 234 RUSSIA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 235 RUSSIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 236 SWITZERLAND OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 237 SWITZERLAND OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 238 SWITZERLAND OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 239 SWITZERLAND OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 240 SWITZERLAND DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 241 SWITZERLAND SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 242 SWITZERLAND IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 243 SWITZERLAND TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 244 SWITZERLAND LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 245 SWITZERLAND TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 246 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 247 SWITZERLAND STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 248 SWITZERLAND OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 249 SWITZERLAND OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 250 SWITZERLAND TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 251 SWITZERLAND INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 252 SWITZERLAND PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 253 SWITZERLAND ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 254 SWITZERLAND OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 255 SWITZERLAND OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 256 SWITZERLAND OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 257 SWITZERLAND OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 258 TURKEY OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 259 TURKEY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 260 TURKEY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 261 TURKEY OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 262 TURKEY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 263 TURKEY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 264 TURKEY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 265 TURKEY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 266 TURKEY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 267 TURKEY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 TURKEY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 TURKEY OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 271 TURKEY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 272 TURKEY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 273 TURKEY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 274 TURKEY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 275 TURKEY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 276 TURKEY OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 277 TURKEY OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 278 TURKEY OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 279 TURKEY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 280 AUSTRIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 281 AUSTRIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 282 AUSTRIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 283 AUSTRIA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 284 AUSTRIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 285 AUSTRIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 286 AUSTRIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 287 AUSTRIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 288 AUSTRIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 289 AUSTRIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 290 AUSTRIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 291 AUSTRIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 292 AUSTRIA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 293 AUSTRIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 294 AUSTRIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 295 AUSTRIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 296 AUSTRIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 297 AUSTRIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 298 AUSTRIA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 299 AUSTRIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 300 AUSTRIA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 301 AUSTRIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 302 NORWAY OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 303 NORWAY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 304 NORWAY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 305 NORWAY OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 306 NORWAY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 307 NORWAY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 308 NORWAY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 309 NORWAY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 310 NORWAY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 311 NORWAY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 312 NORWAY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 313 NORWAY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 314 NORWAY OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 315 NORWAY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 316 NORWAY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 317 NORWAY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 318 NORWAY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 319 NORWAY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 320 NORWAY OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 321 NORWAY OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 322 NORWAY OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 323 NORWAY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 324 HUNGARY OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 325 HUNGARY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 326 HUNGARY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 327 HUNGARY OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 328 HUNGARY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 329 HUNGARY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 330 HUNGARY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 331 HUNGARY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 332 HUNGARY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 333 HUNGARY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 334 HUNGARY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 335 HUNGARY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 336 HUNGARY OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 337 HUNGARY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 338 HUNGARY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 339 HUNGARY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 340 HUNGARY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 341 HUNGARY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 342 HUNGARY OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 343 HUNGARY OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 344 HUNGARY OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 345 HUNGARY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 346 LITHUANIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 347 LITHUANIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 348 LITHUANIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 349 LITHUANIA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 350 LITHUANIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 351 LITHUANIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 352 LITHUANIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 353 LITHUANIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 354 LITHUANIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 355 LITHUANIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 356 LITHUANIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 357 LITHUANIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 358 LITHUANIA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 359 LITHUANIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 360 LITHUANIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 361 LITHUANIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 362 LITHUANIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 363 LITHUANIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 364 LITHUANIA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 365 LITHUANIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 366 LITHUANIA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 367 LITHUANIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 368 IRELAND OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 369 IRELAND OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 370 IRELAND OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 371 IRELAND OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 372 IRELAND DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 373 IRELAND SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 374 IRELAND IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 375 IRELAND TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 376 IRELAND LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 377 IRELAND TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 378 IRELAND NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 379 IRELAND STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 380 IRELAND OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 381 IRELAND OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 382 IRELAND TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 383 IRELAND INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 384 IRELAND PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 385 IRELAND ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 386 IRELAND OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 387 IRELAND OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 388 IRELAND OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 389 IRELAND OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 390 POLAND OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 391 POLAND OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 392 POLAND OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 393 POLAND OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 394 POLAND DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 395 POLAND SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 396 POLAND IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 397 POLAND TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 398 POLAND LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 399 POLAND TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 400 POLAND NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 401 POLAND STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 402 POLAND OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 403 POLAND OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 404 POLAND TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 405 POLAND INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 406 POLAND PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 407 POLAND ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 408 POLAND OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 409 POLAND OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 410 POLAND OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 411 POLAND OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 412 REST OF EUROPE OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
Lista de Figura
FIGURE 1 EUROPE OCULAR PAIN MARKET: SEGMENTATION
FIGURE 2 EUROPE OCULAR PAIN MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE OCULAR PAIN MARKET: DROC ANALYSIS
FIGURE 4 EUROPE OCULAR PAIN MARKET: EUROPE VS REGIONAL ANALYSIS
FIGURE 5 EUROPE OCULAR PAIN MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE OCULAR PAIN MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE OCULAR PAIN MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE OCULAR PAIN MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE OCULAR PAIN MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 EUROPE OCULAR PAIN MARKET: SEGMENTATION
FIGURE 11 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE IS EXPECTED TO DRIVE THE EUROPE OCULAR PAIN MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 OCULAR PAIN WITH EYE DISEASE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE OCULAR PAIN MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE OCULAR PAIN MARKET, AND ASIA-PACIFIC IS PROJECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE OCULAR PAIN MARKET
FIGURE 15 AGEING POPULATION IN THE WORLD (IN MILLIONS)
FIGURE 16 NORTH AMERICA AGEING POPULATION (IN MILLION)
FIGURE 17 EUROPE AGEING POPULATION (IN MILLION)
FIGURE 18 ASIA-PACIFIC AGEING POPULATION (IN MILLION)
FIGURE 19 EUROPE OCULAR PAIN MARKET: BY DISEASE TYPE, 2020
FIGURE 20 EUROPE OCULAR PAIN MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION)
FIGURE 21 EUROPE OCULAR PAIN MARKET: BY DISEASE TYPE, CAGR (2021-2028)
FIGURE 22 EUROPE OCULAR PAIN MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 23 EUROPE OCULAR PAIN MARKET: BY TYPE, 2020
FIGURE 24 EUROPE OCULAR PAIN MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 25 EUROPE OCULAR PAIN MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 26 EUROPE OCULAR PAIN MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 EUROPE OCULAR PAIN MARKET: BY APPLICATION, 2020
FIGURE 28 EUROPE OCULAR PAIN MARKET: BY APPLICATION, 2019-2028 (USD MILLION)
FIGURE 29 EUROPE OCULAR PAIN MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 30 EUROPE OCULAR PAIN MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 EUROPE OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 EUROPE OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 33 EUROPE OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 EUROPE OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 EUROPE OCULAR PAIN MARKET: BY DRUG TYPE, 2020
FIGURE 36 EUROPE OCULAR PAIN MARKET: BY DRUG TYPE, 2019-2028 (USD MILLION)
FIGURE 37 EUROPE OCULAR PAIN MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 38 EUROPE OCULAR PAIN MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 39 EUROPE OCULAR PAIN MARKET: BY POPULATION TYPE, 2020
FIGURE 40 EUROPE OCULAR PAIN MARKET: BY POPULATION TYPE, 2019-2028 (USD MILLION)
FIGURE 41 EUROPE OCULAR PAIN MARKET: BY POPULATION TYPE, CAGR (2021-2028)
FIGURE 42 EUROPE OCULAR PAIN MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 43 EUROPE OCULAR PAIN MARKET: BY END USER, 2020
FIGURE 44 EUROPE OCULAR PAIN MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 45 EUROPE OCULAR PAIN MARKET: BY END USER, CAGR (2021-2028)
FIGURE 46 EUROPE OCULAR PAIN MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 EUROPE OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 48 EUROPE OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 49 EUROPE OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 50 EUROPE OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 EUROPE OCULAR PAIN MARKET: SNAPSHOT (2020)
FIGURE 52 EUROPE OCULAR PAIN MARKET: BY COUNTRY (2020)
FIGURE 53 EUROPE OCULAR PAIN MARKET: BY COUNTRY (2021 & 2028)
FIGURE 54 EUROPE OCULAR PAIN MARKET: BY COUNTRY (2020 & 2028)
FIGURE 55 EUROPE OCULAR PAIN MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 56 EUROPE OCULAR PAIN MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
